Starpharma sells Agrochemicals Business to Agrium for $35M
Starpharma Holdings announced that it has completed a transaction to sell its agrochemicals and Priostar business (Starpharma Agrochemicals) to Agrium for $35 million in cash consideration. The
Starpharma Agrochemical business will be operated by Agrium’s wholly-owned subsidiary, Loveland Products. Starpharma Agrochemicals is comprised of key patents and technical know-how as well as a small number of staff dedicated solely to Priostar dendrimers and agrochemicals operations.
More info : www.agrium.com/en/investors/news-releases
Bicycle Therapeutics raises $52M
Vertex Ventures has led a $52 million Series B round for Cambridge UK biotech business Bicycle Therapeutics to accelerate development of multiple drug candidates. The company will now further develop a range of candidates, including its lead molecule, BT1718, a first-in-class drug for cancers of high unmet need. Bicycle CEO Dr Kevin Lee said: “This financing represents an important validation of our approach while providing Bicycle with the resources to continue to advance our pipeline and translate our bicyclic peptide technology into important new treatment options for patients.”
More info : http://www.businessweekly.co.uk/news/biomedtech/bicycle-therapeutics-raises-52m-series-b-cash
F-star tees up potential €1bn antibodies windfall from Merck
The UK company, F-star, has expanded its relationship with Merck through a new strategic collaboration to develop and commercialise five bispecific antibodies in immuno-oncology, including F-star’s lead asset FS118. F-star will receive up to €115 million in R & D funding and milestone payments over the first two years and further milestone-based payments endemic in the contract. Merck has the option to acquire the programmes with a potential deal value of more than €1 billion.
More info : http://www.businessweekly.co.uk/news/biomedtech/f-star-tees-potential-%E2%82%AC1bn-antibodies-windfall-merck
Déjanos un comentario